Strides Pharma Science · NSE: STAR · BSE: 532531

Q2 FY23 results · Jul–Sep 2022

Strides Pharma Science reported revenue from operations of ₹897.10 crore (up 24.3% from Q2 FY22) and net profit of ₹18.90 crore for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY23	Q2 FY22	YoY	Q1 FY23	QoQ
Revenue from operations	897.10	721.47	+24.3%	940.07	−4.6%
Other income	23.46	22.21	+5.6%	13.55	+73.2%
Total income	920.56	743.68	+23.8%	953.62	−3.5%
Profit before share of associates & JVs and tax	6.77	(151.37)	Turned profit	(107.01)	Turned profit
Share of profit/(loss) of associates & JVs	(44.84)	(23.37)		(56.39)
Net profit for the period	18.90	(167.98)	Turned profit	(135.33)	Turned profit
Attributable to shareholders of the company	22.82	(162.56)	Turned profit	(135.89)	Turned profit
EPS, basic (₹)	2.54	(18.12)	Turned profit	(15.13)	Turned profit
Net margin (%)	2.1	-23.3		-14.4

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY23	Q2 FY22	YoY	Q1 FY23	QoQ
Revenue from operations	481.24	575.00	−16.3%	423.19	+13.7%
Other income	20.47	22.41	−8.7%	7.46	+174.2%
Total income	501.71	597.41	−16.0%	430.65	+16.5%
Profit before tax	(44.07)	24.28	Turned loss	(103.88)	Loss narrowed
Net profit for the period	(4.00)	18.52	Turned loss	(66.25)	Loss narrowed
EPS, basic (₹)	(0.44)	2.06	Turned loss	(7.38)	Loss narrowed
Net margin (%)	-0.8	3.2		-15.7

Consolidated

Filed with BSE: 15 Nov 2022, 17:54 IST
Board meeting: 14 Nov 2022
Period: 01 Jul 2022 to 30 Sep 2022
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 15 Nov 2022, 17:54 IST
Board meeting: 14 Nov 2022
Period: 01 Jul 2022 to 30 Sep 2022
Review status: Unaudited
Source: XBRL filing on BSE